Impact of point-of-care birth test-and-treat on clinical outcomes among infants with HIV: A cluster randomized trial in Mozambique and Tanzania
Ilesh V Jani,Issa Sabi,Kira Elsbernd,Bindiya Meggi,Arlete Mahumane,Anange Fred Lwilla,Kassia Pereira,Siriel Boniface,Raphael Edom,Joaquim Lequechane,Falume Chale,Nhamo Chiwerengo,Nyanda E Ntinginya,Chishamiso Mudenyanga,Mariana Mueller,Martina Rauscher,Michael Hoelscher,Nuno Taveira,W Chris Buck,Arne Kroidl,the LIFE study consortium,Lise Ellyin,Araújo Patricio,Dadirai Mutsaka,Lara Samuel,Sergey Bocharnikov,Timothy Bollinger,Wilson Simbine,Abhishek Bakuli,Cornelia Lueer,Elmar Saathoff,Fidelina Zekoll,Friedrich Rieß,Otto Geisenberger,Rute Marcelino,Absalao Zumba,Daniel Machavae,Adolfo Vubil,Ana Duajá,Jacinto Adolfo Ndarissone,Joao Manuel,Maria Maviga,Nalia Ismael,Jorge Morais,Nedio Mabunda,Adolfo Vubil,Fatima Mecupa,Amina de Sousa,Abisai Kisinda,Chacha Mangu,Doreen Pamba,Festina Paschal,Hellen Mahiga,Janeth Stephen,Lilian Njovu,Magreth Haule,Oliver Lyoba,Theodora Mbunda,Willyhelmina Olomi
DOI: https://doi.org/10.1093/cid/ciae530
IF: 20.999
2024-11-10
Clinical Infectious Diseases
Abstract:We assessed the impact of point-of-care (PoC) test-and-treat at birth on clinical outcomes and viral suppression among HIV-positive infants in Mozambique and Tanzania. This cluster-randomized trial allocated health facilities to intervention, providing PoC-testing and antiretroviral treatment (ART) at birth and week 4-8, or control, starting these at week 4-8. The primary outcome was proportions of clinical events (mortality, morbidity, retention, virological failure, toxicity) among HIV-positive infants at month-18. We estimated incidence rate ratios adjusted for timing of HIV-detection (aIRR) and reported viral suppression <1000 copies/mL. Among 6602 neonates enrolled October 2019-September 2021, 125 were diagnosed HIV-positive by week 12. In the intervention arm, 38/69 (55.1%) were diagnosed at birth with 35 initiating ART within two days. In the control arm, 27/56 (48.2%) were retrospectively detected HIV-positive at birth, of whom 6/56 (10.7%) died or were lost to follow-up before testing. Median age at ART initiation was 6 (intervention) versus 33 days (control). Birth test-and-treat was not associated with a significant reduction in clinical outcomes up to month-18 [53 (76.8%) versus 48 (85.7%); aIRR 0.857; 95% CI 0.505–1.492], but showed a 68% relative reduction in 6-month mortality. Viral suppression was poor overall, but improved in the intervention group at month 18 (65.7% versus 29.6%; p=0.005). PoC test-and-treat at birth is feasible in resource-poor settings and resulted in clinically-relevant reduction of early infant mortality, though improved clinical outcomes were not sustained to month-18. Poor viral suppression may undermine early survival benefits, calling for better paediatric treatments and tailored adherence interventions. This graphical abstract is also available at Tidbit: https://tidbitapp.io/institutional-portal/clinical-infectious-diseases/tidbits/impact-of-point-of-care-birth-test-and-treat-on-clinical-outcomes-among-infants-with-hiv-a-cluster-randomized-trial-in-mozambique-and-tanzania-b24b5824-f7c1-4058-aba0-d1aaeb7c4117/update
immunology,infectious diseases,microbiology